Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-LNC1011 in PSMA-positive mCRPC
NCT06809426Completed
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 177Lu-LNC1011 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoints: Difference in PSA changes before and after treatment and Objective Remission Rate. Started Aug 2023; status: completed.
02
Drugs
177Lu-LNC1011
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06809426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809426.